A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia

Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review

(2018) Juan Eduardo Megías-Vericat et al.   ANNALS OF HEMATOLOGY

A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia

(2018) Amy Y. Wang et al.   Journal of Hematology & Oncology

Localization of AML-related nucleophosmin mutant depends on its subtype and is highly affected by its interaction with wild-type NPM

(2017) Barbora Brodská et al.   PLoS One

XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase II  to the Nucleus

(2016) P. Ranganathan et al.   CLINICAL CANCER RESEARCH

Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies

(2016) Z A Hing et al.   LEUKEMIA

Treatment for relapsed acute myeloid leukemia

(2012) Yishai Ofran et al.   CURRENT OPINION IN HEMATOLOGY

Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish

(2010) N. Bolli et al.   BLOOD

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

(2010) D. Grimwade et al.   BLOOD

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications

(2009) B Falini et al.   LEUKEMIA